UNSPSC 51284126: Cefditoren pivoxil

This classification denotes a cephalosporin antibiotic with the molecular formula C25H28N6O7S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 78THA212DH, chemically known as cefditoren pivoxil, me-1207, meiact but more generally known as cefditoren pivoxil, which bears US NIH Compound Identifier 444006. European Medicines Agency schedules Cefditoren pivoxil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01112MIG.

Most nations, for tariff and trade purposes, schedule cefditoren pivoxil under HS 29419000 and SITC 54139. As of Q4 2014, CEFDITOREN PIVOXIL remains US FDA's Preferred Term for this commodity. Cefditoren pivoxil bears US NLM identifiers UMLS ID C0245519 and NCI Concept Code C47434. SMILES: CC1C(SCN1)/C=C\C2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\OC)/C4CSC(N4)N)SC2)C(=O)OCOC(=O)C(C)(C)C.

UNSPSC 51284126 Cefditoren pivoxil is a Commodity code for a specific oral cephalosporin antibiotic formulation, yet the recent state and local procurement activity tagged to this code does not reflect purchases of cefditoren pivoxil itself. Instead, the opportunities posted under this code involve pharmaceutical warehouse piggyback contracts and naloxone procurement — neither of which align with the code's stated product scope. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC for Doxycycline Hyclate and Ciprofloxacin Hydrochloride tablets under an IFB process, while Seminole County, Florida solicited naloxone and drug deactivation systems through a competitive bid. The mismatch between the code's narrow pharmaceutical product definition and the actual procurement activity suggests either that the code has been misapplied by issuing bodies or that state and local purchasing offices are using it as a catch-all for pharmaceutical acquisitions beyond cefditoren pivoxil specifically.

The geographic activity appears concentrated in Florida and Illinois based on recent postings, though the limited sample does not support a broader regional characterization. Issuing bodies include a state department of health and a county government, both pursuing pharmaceutical acquisitions through established cooperative-purchasing vehicles or direct competitive bids. The representative recent opportunities — the Illinois Department of Public Health piggyback award (closed as of August 28, 2026) and the Seminole County IFB for naloxone (response deadline July 26, 2023) — both involved multi-year terms and volume-based procurement structures typical of public-health pharmaceutical procurement. However, the consistent tagging mismatch across these opportunities signals that business development professionals should verify actual commodity scope with issuing bodies before pursuing work under this code.